# A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM)

> **NCT04893785** · PHASE2 · RECRUITING · sponsor: **National Cancer Institute, Naples** · enrollment: 35 (estimated)

## Conditions studied

- Lung Neuroendocrine Neoplasm
- GEP Neuroendocrine Tumor

## Interventions

- **DRUG:** Cabozantinib and Temozolomide

## Key facts

- **NCT ID:** NCT04893785
- **Lead sponsor:** National Cancer Institute, Naples
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-06-15
- **Primary completion:** 2025-01
- **Final completion:** 2026-12
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2024-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04893785

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04893785, "A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04893785. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*